The Cooper Companies, Inc. (COO) stock analysis

Healthcare · Medical Instruments & Supplies

From the 10-K filed 2025-12-05

Business type: Treadmill

How it makes money

Cooper earns revenue by selling contact lenses and women's health products through two segments, driven by global demand for single-use and monthly replacement lenses.

Cooper operates through two segments: CooperVision, which manufactures spherical, toric, and multifocal contact lenses and myopia management products, and CooperSurgical, which provides fertility products, medical devices, and cord blood storage. Profitability depends heavily on customer adoption of preferred wearing modalities, such as single-use daily lenses and monthly frequent replacement silicone hydrogel products like the Biofinity brand.

What protects it: the moat

Management claims protection through patents, trademarks, trade secrets, and continuous technological innovation, alongside proprietary regulatory approvals like the MiSight 1 day lens.

The company relies on intellectual property rights, patent enforcement, and brand recognition to defend its market position. Management states that it monitors competitive products and enforces its trademark and patent rights globally, while also relying on technical know-how and specialized product approvals such as the FDA-indicated MiSight 1 day lens for myopia progression.

What growth costs

The filing does not disclose specific figures for maintaining or growing earnings through capital expenditures, R&D, or working capital.

While the company mentions expanding operations, entering new foreign jurisdictions, and acquiring companies, products, and services to build out CooperSurgical's distribution system, the provided text does not state exact monetary amounts required for maintaining or growing these investments.

What could damage it

Consolidation among customer bases and retail chains creates large key account concentrations, meaning any relationship disruption could permanently impair earnings.

As customer bases consolidate into centralized large customer groups and retail chains, individual accounts represent a substantially larger proportion of the business. If these key accounts reduce purchases, switch to competitors, or disrupt their relationship with Cooper, the resulting revenue loss would directly impair overall earnings.

About The Cooper Companies, Inc.

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

More on COO

Other companies in Medical Instruments & Supplies